Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiaozhenfang granule for prevention of EGFR inhibitor-induced dermal toxicity in NSCLC
ChiCTR2500095160Phase 2Recruiting
- Sponsor
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Start
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in EGFR inhibitor-induced skin toxicity and non-small cell lung cancer (NSCLC) comparing EGFRI + Xiaozhenfang granule with Control: EGFRI + Xiaozhenfang granule placebo (2 arms). Primary endpoint: NCI-CTCAE v5.0 grade of adverse reactions at week 4. Started Jan 2025; status: recruiting.
02
Drugs
Xiaozhenfang
03
Conditions
EGFR inhibitor-induced skin toxicitynon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500095160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095160.